Enfusion, Inc.
ENFN · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -4.14 | -0.87 | 0.65 | 0.00 |
| FCF Yield | 3.27% | 1.87% | 0.75% | -0.61% |
| EV / EBITDA | 148.48 | 38.08 | -137.05 | -4.81 |
| Quality | ||||
| ROIC | 1.93% | 10.36% | -11.37% | -282.15% |
| Gross Margin | 67.82% | 66.97% | 68.67% | 71.49% |
| Cash Conversion Ratio | 8.86 | 2.77 | -1.07 | 0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.27% | 16.04% | 23.63% | 23.69% |
| Free Cash Flow Growth | 94.49% | 156.43% | 174.71% | -144.84% |
| Safety | ||||
| Net Debt / EBITDA | -5.55 | -0.92 | 9.89 | 0.24 |
| Interest Coverage | 0.00 | 0.00 | -28.97 | -60.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 7.71 | 0.00 |
| Cash Conversion Cycle | 53.03 | 44.69 | 97.02 | 30.57 |